拉米夫定联合母牛分枝杆菌菌苗治疗慢性乙型肝炎  

Lamivudine combined with mycobacterium bovis vaccine in the treatment of patients with chronic hepatitis B

作　　者：苏海滨[1] 王慧芬[1] 季伟[1] 李捍卫[1] 李莉[1] 陈国凤[1] 吴勤[1] 

机构地区：[1]北京市解放军第302医院十三科,100039

出　　处：《实用肝脏病杂志》2006年第4期221-222,共2页Journal of Practical Hepatology

摘　　要：目的观察拉米夫定联合母牛分枝杆菌菌苗治疗慢性乙型肝炎的疗效。方法选择HBsAg,HBeAg,HBV DNA均阳性半年以上的患者84例,分为治疗组54例,对照组30例。两组均给予拉米夫定0.1g/d,治疗组加用母牛分枝杆菌菌苗22.5μg,深部肌肉注射,每周一次。共24周。结果治疗结束时两组ALT,TBIL复常率无显著差异,但HBeAg,HBV DNA阴转率差异显著。联合治疗组无应答率29.6%,低于单用拉米夫定组。有效率达70.4%,显著高于单用拉米夫定组。结论拉米夫定联合免疫调节剂母牛分枝杆菌菌苗能提高抗HBV的疗效。Objective To observe the effect of treatment with lamivudine combined with mycobacterium bovis vaccine on chronic hepatitis B. Methods 84 cases with chronic hepatitis B who were positive in HBsAg, HBeAg and HBV DNA were divided to treatment group （54 cases） and control group （30 cases）. Both group treated with lamivudine （0.1 g/d）, but mycobacterium bovis vaccine （22. 5μg, IM, once a week） was also used in treatment group. The treatment last for 24 weeks. Result At the end of treatment, the normalization rate of ALT and TBil had no significantly difference between two groups, but the negative rate of HBeAg and HBV DNA had significantly difference. Non-response rate in treatment group was 29.6%, much lower than in control group treated with lamivudine alone. Effective power in treatment group was 70. 4%,much higher than in control group. Conclusion Lamivudine combined with mycobacterium bovis vaccine can enhance the therapeutic effect on the treatment for chronic hepatitis B.

关 键 词：慢性乙型肝炎 拉米夫定 母牛分枝杆菌菌苗 联合治疗 

分 类 号：R512.62[医药卫生—内科学]